Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

Analysts anticipate a surge in US-China biotech deals, with out-licensing expected to be particularly strong. This optimism stems from reports that the US Treasury Department is drafting plans that indicate Washington is moving away from imposing broad restrictions on such collaborations. This potential shift in US policy, coupled with Beijing's ambitious five-year plan for its biotech sector, is creating a favorable environment for Chinese healthcare firms. Nomura's head of China healthcare research, Jialin Zhang, stated that these deals are poised to "ride on a high tide" due to these favorable conditions.